Month: February 2023

HERE and Cognizant collaborate to provide location insights and analytics for global businesses

HERE Technologies and Cognizant to work together on delivering digital customer experiences with the help of location data. This partnership provides real-time location insights and analytics to businesses across vertical industries including retail, technology, communications, manufacturing, logistics and automotive. Mumbai – HERE Technologies, the leading location data and technology platform, announced today

Read more

Canon Medical Extends Clinically Intelligent AI-driven Enterprise Platform to include Pathology Through Partnership with Tribun Health

MINNETONKA, Minn., Feb. 28, 2023 (GLOBE NEWSWIRE) — Canon Medical Informatics, Inc. has extended its Enterprise Imaging (EI) suite of solutions to include pathology through its partnership with Tribun Health. This provides new capability for healthcare organizations to efficiently include pathology into their enterprise imaging plans as part of their

Read more

Azerion publishes Interim Unaudited Q4 and FY 2022 Results

Delivery on 2022 targets with profitable growth outlook Highlights of Q4 2022 Delivery of 2022 targets. Full year 2022 Net revenue of EUR 453 million (guidance of at least EUR 450 million), with Adjusted EBITDA of EUR 52 million (guidance of at least EUR 50 million), reflecting almost 10% organic growth in 2022. Record performance […]

Read more

Azerion to propose cancellation of shares held in treasury

Amsterdam, 28 February 2023 – Today, Azerion has announced its intention to cancel up to 58,690,961 ordinary shares held in treasury, in order to reduce the number of shares outstanding. A resolution for the cancellation of the treasury shares will be submitted at the next Annual General Meeting (AGM), which

Read more

Junshi Biosciences Announces Ongericimab (anti-PCSK9 mAb) Met Primary Endpoints in Two Phase 3 Clinical Studies

SHANGHAI, China, Feb. 27, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the successful completion of two randomized, double-blind, placebo-controlled, multi-center phase III clinical studies (Study

Read more

Recent News